Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Conversation
The Conversation
Jack Janetzki, Lecturer in Pharmacy and Pharmacology, Adelaide University

A new ADHD drug targets three brain chemicals instead of two. Here’s what that means

Israel Sebastian/Getty Images

A new medicine for attention-deficit hyperactivity disorder (ADHD) has just entered the treatment toolbox: centanafadine, a once-a-day tablet sold under the brand name Simtriyo.

It has been approved in the United States for adults and children aged six years and older but isn’t yet available in Australia.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.